BAVARIAN NORDIC/S (BVNRY) to Release Quarterly Earnings on Wednesday

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) is set to issue its quarterly earnings data before the market opens on Wednesday, May 22nd. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

Shares of BVNRY opened at $6.64 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.84 and a current ratio of 6.15. BAVARIAN NORDIC/S has a 1 year low of $5.92 and a 1 year high of $10.78.

Separately, Zacks Investment Research cut shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th.

ILLEGAL ACTIVITY WARNING: This story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/20/bavarian-nordic-s-bvnry-to-release-quarterly-earnings-on-wednesday.html.

About BAVARIAN NORDIC/S

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Read More: What is the yield curve?

Earnings History for BAVARIAN NORDIC/S (OTCMKTS:BVNRY)

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.